Company Overview
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +15.02% |
| 6 Months: | -9.91% |
| 3 Months: | -30.43% |
| 1 Month: | -21.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.50 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 43.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NGNE Neurogene Inc. R2KR3KPHARMA | 24.28 | -4.82 | $485.88M | 0.00% | -37.96% | -45.31% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | 925.00K | 0 | - | 0 | 0 | - |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.99M | -12.07M | - | 2.69M | -15.20M | - | -428.00K | -59.52M | -9.07M | -9.77M | -2.25M | -14.95M | -15.12M | -15.45M | -15.37M | -15.87M | -13.61M | -13.04M | -12.60M | -15.22M | -18.78M | -20.13M | -22.18M | -25.92M | -26.08M | -23.80M | -33.35M |
| Net Income | -1.01M | -811.50K | -3.37M | -4.23M | -5.42M | -6.28M | -6.41M | -4.75M | -5.04M | -6.71M | -10.90M | -8.15M | -8.32M | -13.77M | -11.83M | -14.62M | 2.92M | -14.99M | -2.21M | -1.00K | -59.13M | -8.64M | -9.75M | -2.25M | -14.95M | -15.13M | -15.45M | -15.35M | -15.69M | -13.07M | -12.26M | -11.86M | -14.58M | -16.92M | -18.49M | -20.22M | -22.65M | -22.02M | -20.95M | -30.93M |
| Diluted EPS | -8.48 | - | - | -1.28 | - | - | - | - | - | - | - | - | - | -0.59 | - | - | 0.12 | - | - | - | - | -0.18 | -0.20 | -0.04 | -0.27 | -0.27 | -0.28 | -0.28 | -0.28 | -1.18 | -0.26 | -26.68 | -32.67 | -1.00 | -1.09 | -1.19 | -1.08 | -1.05 | -0.99 | -1.39 |
| R&D Expense | 572.97K | 1.25M | 3.03M | 1.88M | 4.55M | 5.32M | 4.57M | 3.62M | 3.69M | 4.88M | 9.23M | 6.13M | 5.78M | 10.47M | 8.46M | 10.51M | 18.00M | 10.71M | 104.00K | - | - | 5.50M | 4.84M | 6.22M | 9.71M | 9.82M | 9.90M | 10.70M | 10.96M | 9.47M | 10.28M | 10.32M | 11.61M | 13.54M | 15.74M | 16.29M | 17.76M | 19.37M | 17.24M | 25.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 25.00M | - | - | - | - | 0 | 925.00K | 0 |
| Operating Income | - | - | - | - | -37.65M | -51.12M | -32.62M | -70.96M | -33.73M | -60.70M | -56.52M | -55.58M | -82.61M | -103.33M |
| Net Income | -7.71M | -8.73M | -24.03M | -21.86M | -37.00M | -50.18M | -31.59M | -69.44M | -33.28M | -60.69M | -55.19M | -36.32M | -75.14M | -90.35M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.64 | -1.10 | -1.04 | - | -4.28 | -4.24 |
| R&D Expense | 6.05M | 7.60M | 18.08M | 15.80M | 28.38M | 36.27M | 41.79M | - | - | 39.16M | 47.51M | 44.39M | 60.92M | 75.01M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 15.65M | - | 41.42M | 113.34M | 154.38M | 110.33M | 77.62M | 147.02M | 210.52M | 163.26M | 109.27M | 222.57M | 335.73M | 288.60M |
| Total Equity | -39.31M | -51.10M | -65.69M | -65.39M | 36.15M | 108.42M | 144.66M | 98.89M | 72.67M | 141.69M | 191.22M | -91.88M | -145.74M | 186.02M | 310.38M | 264.89M |
| Cash & Equivalents | 9.24M | 2.00M | 11.01M | - | 14.91M | 39.53M | 32.30M | 52.03M | 76.93M | 143.09M | 192.56M | 142.47M | 82.02M | 148.21M | 136.59M | 103.84M |
| Total Liabilities | - | - | 7.48M | - | 5.28M | 4.92M | 9.72M | 11.44M | 4.95M | 5.34M | 19.30M | 20.40M | 10.64M | 36.55M | 25.36M | 23.72M |
| Current Liabilities | - | - | 2.62M | - | 5.20M | 4.79M | 9.52M | 10.96M | 4.63M | 4.74M | 7.89M | 8.64M | 6.65M | 22.97M | 15.16M | 16.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -30.23M | -44.72M | -31.58M | -15.39M | -24.57M | -47.56M | -52.82M | -51.42M | -70.60M | -77.17M |
| Investing Cash Flow | - | - | - | - | -48.06M | 64.01M | 55.95M | -688.00K | -2.22M | -3.26M | -2.23M | 25.64M | -125.26M | 14.00M |
| Financing Cash Flow | - | - | - | - | 71.11M | 423.00K | 570.00K | 82.24M | 77.14M | 732.00K | 66.53M | 92.48M | 184.07M | 30.43M |
| Capital Expenditure | -6.45K | -11.00K | -114.00K | -26.00K | -713.00K | -494.00K | -49.00K | -879.00K | -2.22M | -3.26M | -2.23M | -321.00K | -808.00K | -1.18M |
| Free Cash Flow | - | - | - | - | -30.94M | -45.21M | -31.63M | -16.27M | -26.79M | -50.82M | -55.05M | -51.74M | -71.41M | -78.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | -130.5% | - | - | - | - | - | -8,930.3% | - |
| Net Margin % | - | - | - | - | - | - | -126.3% | - | - | - | - | - | -8,123.7% | - |
| ROE % | 15.1% | 13.3% | -66.5% | -20.2% | -25.6% | -50.7% | -43.5% | -49.0% | -17.4% | 66.1% | 37.9% | -19.5% | -24.2% | -34.1% |
| ROCE % | - | - | - | - | -26.0% | -51.4% | -44.7% | -49.9% | -16.6% | -39.3% | -55.1% | -27.8% | -25.8% | -38.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Samsara BioCapital, LLC | 8.58% | 1.72M | $45.33M |
| 2 | Casdin Capital, LLC | 7.72% | 1.55M | $40.80M |
| 3 | Redmile Group, LLC | 7.06% | 1.41M | $37.28M |
| 4 | RTW Investments LP | 6.81% | 1.36M | $35.97M |
| 5 | EcoR1 Capital, LLC | 6.35% | 1.27M | $33.56M |
| 6 | Blackrock Inc. | 5.29% | 1.06M | $27.93M |
| 7 | Baker Bros. Advisors, LP | 4.96% | 991.69K | $26.18M |
| 8 | Balyasny Asset Management LP | 4.09% | 818.71K | $21.61M |
| 9 | Trails Edge Capital Partners, LP | 3.57% | 714.88K | $18.87M |
| 10 | Toronto Dominion Bank | 3.40% | 681.34K | $17.99M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NGNE
New Rett syndrome data will examine how quickly a gene therapy’s instructions become active. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOOGU0UGhYeTdQMFhSTzAtYjZxT0d0QlJFaTljYmI2bW9lenpsWWRTVGVkY2hjUktYLXMtV3o3Q0ZRODVLcnFuWWNQZ1hsNFR2MXBsdEhIVGtnR1pXY3o4NVpCMkZkNGFkUFZkcDJ5TmZnYUxkeHVvU24wZlA2Q1g3Wi1tNVgzaVlINUZ0Zk…
NGNE Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFA5UThBbFpNLVZlbW9nOGx0ZkJma2dkWGJlTEVzaWJzV0huMkYyLTBhbFFkTDZrXzhqZzFsS2NaN18yUWFMMzJIVnVGWC1YakFPWm4tWER3eEpXT2ZFMFM0cDNHQTEyM0ZiMkEwVkl4U1JvZFVwVGhCRERB?oc=5" target="_blank">NGN…
Neurogene stock a new Overweight at J.P. Morgan (NGNE:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPZ3VoTlNXZWFTa3FEektGS0JIU2VOSmp0aVR5LUgyRWJzOHdEaUVRMXpkaEFCSWJTcW5CMVpaNTVvWEFRS1pSQ1k1a2xVTlBIbDlRdEZWVmRPUnhJOUdnOWtHQWo5dFNCd0EwUTZOTGZPVDZyZ1BsZ1hsWGJxd0s3azB0Nkk?oc=5" targ…
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPMDNuU3ZiTHlTVVk0dEtfai1NSTFZVWVuWGx3S3A5NGt3b2F4NkdNcWZ2TlpfU1RLaTYxQzVsQnZxY2RZZUE1bTVHRVBDa1U2OVdzMndydGpHc0k3RjhlNVJJajRiQ3A0SHZjWnZkWk1BcFFrcGRidEdrOHJwQjd5N2ZsbGVaV0JJUTNzMU…
$NGNE stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPR3ZxblctTk1QVlhDRXNXbHhCSGhjUXI5bjZHV3k5UzhXMzJLWklTbzk3eGllZk1YaEF3ZVBYVjV2YWREX0FwTzkyeHdNaHhfUlI0eWp5dFlaR3Z0VUhxb2FGbFo3cHNQVnVvV0diQlJUQWJ6TG1UZ0czR2lyVXZQRGNkSl9nQkwwQ1R2M2…
Neurogene Inc. (NGNE) Stock Price & News - Syfe
<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE1lYk5GNkowLWhrLXl0M25KNEdXQkdSNHVCQWNuSmdmQm9CVE83MG5HYTVETTY0TTBmSlJLZTlCMTAtZDBjUmVWMU80OA?oc=5" target="_blank">Neurogene Inc. (NGNE) Stock Price & News</a> <font col…
NGNE — Frequently Asked Questions
What is the current share price of Neurogene Inc. (NGNE)?
As of 2026-10-22 16:30 PDT, Neurogene Inc. (NGNE) trades at $24.28 on NasdaqGM. Its 52-week range is $16.37 to $42.84.
What is the market capitalisation of NGNE?
Neurogene Inc. (NGNE) has a market capitalisation of $485.88M on NasdaqGM.
What is the P/E ratio of NGNE?
NGNE trades at a trailing price-to-earnings (P/E) ratio of -4.82. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 2.34.
What is the return on equity (ROE) of NGNE?
NGNE has a return on equity (ROE) of -45.31%. Its return on capital employed (ROCE) is -37.96%.
Is NGNE a good stock to buy?
This page provides a data-driven analysis of Neurogene Inc. (NGNE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.